SecBot SecBot

SXTP

60 DEGREES PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001946563 Biotech & Drug Discovery
$0.8700 −0.01 (−0.68%)
Oct 23 4:00 PM ET · prev $0.8760
Market cap
$3.1M
Nano cap
Median target
🔒 Subscribers only
1 year
−85.2%
from $5.88 · Oct 24
30 days
−24.3%
from $1.15
52-week range
$0.8270–5.92
−85% from high · low Oct 19
Avg volume 20D
217.0K
Oct 6 spike 2.45M
Short interest
133.4K
≈3.8% of shares · −38.3%
Days to cover
1.6
at average volume
Insider net
+$10.1K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 3 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6
Strongest NEUTRAL 60 Degrees Pharmaceuticals announced it will conclude enrollment in its Phase 2 severe babesiosis study at…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $10.1K at an average $1.38. No open-market sales. Price is 37% below their cost.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −38.3% to 133.4K shares. 1.6 days to cover, ≈3.8% of shares.

  • TrendDOWNTREND

    16% below its 50-day average. New closing low $0.8270 on Oct 19.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM13,592$23.9K
BARCLAYS PLCTRIM1,052$1.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
May 22, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
May 20, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$10.1K
bought · 1 insider
$0
sold · 0 insiders
−36.9%
vs their $1.38 cost
DateInsiderTypeValue
Jun 12, 2026
DOW GEOFFREY S
President and CEO
BUY$10.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 6, 2026
FDA
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sNDA meeting with FDA.
Oct 1, 2026
Press release
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
60 Degrees Pharmaceuticals will release interim severe babesiosis study data and host a KOL investor webinar on October 6, 2026.
Aug 14, 2026
Earnings
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Jul 30, 2026
Offering
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Jul 8, 2026
Press release
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease…

Short side

FINRA· Sep 30, 2026
133,355
shares short
-38.3%
vs prior settlement
1.6
days to cover
≈3.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
60 Degrees Pharmaceuticals filed an 8-K furnishing an updated investor presentation (October 23, 2026) detailing…
8-K — Impact 4/10
Oct 6, 2026 Press
60 Degrees Pharmaceuticals announced it will conclude enrollment in its Phase 2 severe babesiosis study at 30 patients…
Impact 6/10
Oct 6, 2026 FDA
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sND
Oct 6, 2026 SEC
60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized severe babesiosis study at 30…
8-K — Impact 5/10
Aug 26, 2026 SEC
60 Degrees Pharmaceuticals' S-3 shelf registration (File No. 333-298349) became effective on August 25, 2026. This…
EFFECT — Impact 6/10
Jul 30, 2026 Press
Sixty Degrees Pharmaceuticals announced a private placement of 574,713 shares (or pre-funded warrants) with Series A…
Impact 6/10
Jun 30, 2026 Inst.
UBS Group AG — TRIM
13,592 shares ($23.9K)
Jun 30, 2026 Inst.
BARCLAYS PLC — TRIM
1,052 shares ($1.9K)

SecBot reports

5 filings · 6 press releases · 0 bullish · 3 bearish · 2 neutral
All SXTP filing & press-release reports (11)